These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21085192)

  • 1. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome.
    van der Fits L; van Kester MS; Qin Y; Out-Luiting JJ; Smit F; Zoutman WH; Willemze R; Tensen CP; Vermeer MH
    J Invest Dermatol; 2011 Mar; 131(3):762-8. PubMed ID: 21085192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in Sézary syndrome.
    van der Fits L; Out-Luiting JJ; van Leeuwen MA; Samsom JN; Willemze R; Tensen CP; Vermeer MH
    J Invest Dermatol; 2012 Feb; 132(2):440-7. PubMed ID: 21938013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.
    Zhang C; Li B; Gaikwad AS; Haridas V; Xu Z; Gutterman JU; Duvic M
    J Invest Dermatol; 2008 Nov; 128(11):2728-2735. PubMed ID: 18496567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EPHA4 is overexpressed but not functionally active in Sézary syndrome.
    Hameetman L; van der Fits L; Zoutman WH; Out-Luiting JJ; Siegal G; de Esch IJ; Vermeer MH; Tensen CP
    Oncotarget; 2015 Oct; 6(31):31868-76. PubMed ID: 26376612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sèzary syndrome patients.
    Kohnken R; Kodigepalli KM; Mishra A; Porcu P; Wu L
    Leuk Res; 2017 Jan; 52():58-66. PubMed ID: 27889686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
    van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
    J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of the MIR155 host gene in physiological and pathological processes.
    Elton TS; Selemon H; Elton SM; Parinandi NL
    Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells.
    Eriksen KW; Kaltoft K; Mikkelsen G; Nielsen M; Zhang Q; Geisler C; Nissen MH; Röpke C; Wasik MA; Odum N
    Leukemia; 2001 May; 15(5):787-93. PubMed ID: 11368440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the IL-21-STAT3 axis as therapeutic target for Sézary syndrome.
    van der Fits L; Out-Luiting JJ; Tensen CP; Zoutman WH; Vermeer MH
    J Invest Dermatol; 2014 Oct; 134(10):2639-2647. PubMed ID: 24756111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
    Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
    J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
    Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
    Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome.
    Yoon JS; Newton SM; Wysocka M; Troxel AB; Hess SD; Richardson SK; Lin JH; Benoit BM; Kasprzycka M; Wasik MA; Rook AH
    J Invest Dermatol; 2008 Feb; 128(2):473-80. PubMed ID: 17713571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-positive CD4(+)CD8(+) Sézary syndrome: an unusual phenotype with an aggressive clinical course.
    Wu R; Zippin JH; Magro C
    Cutis; 2014 Feb; 93(2):E18-25. PubMed ID: 24605355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD164 identifies CD4
    Benoit BM; Jariwala N; O'Connor G; Oetjen LK; Whelan TM; Werth A; Troxel AB; Sicard H; Zhu L; Miller C; Takeshita J; McVicar DW; Kim BS; Rook AH; Wysocka M
    Arch Dermatol Res; 2017 Jan; 309(1):11-19. PubMed ID: 27766406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIR3DL2/CpG ODN interaction mediates Sézary syndrome malignant T cell apoptosis.
    Ghazi B; Thonnart N; Bagot M; Bensussan A; Marie-Cardine A
    J Invest Dermatol; 2015 Jan; 135(1):229-237. PubMed ID: 25007046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel mouse model for Sézary syndrome using xenotransplantation of Sézary cells into immunodeficient RAG2(-/-) γc(-/-) mice.
    van der Fits L; Rebel HG; Out-Luiting JJ; Pouw SM; Smit F; Vermeer KG; van Zijl L; Tensen CP; Weijer K; Vermeer MH
    Exp Dermatol; 2012 Sep; 21(9):706-9. PubMed ID: 22897578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma.
    Brender C; Nielsen M; Kaltoft K; Mikkelsen G; Zhang Q; Wasik M; Billestrup N; Odum N
    Blood; 2001 Feb; 97(4):1056-62. PubMed ID: 11159537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
    Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
    Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
    Wu J; Nihal M; Siddiqui J; Vonderheid EC; Wood GS
    J Invest Dermatol; 2009 May; 129(5):1165-73. PubMed ID: 18923451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma.
    García-Colmenero L; González J; Sandoval J; Guillén Y; Diaz-Lagares A; Andrades E; Iglesias A; Nonell L; Pujol RM; Bigas A; Espinosa L; Gallardo F
    Cells; 2020 Dec; 9(12):. PubMed ID: 33333886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.